Drug intelligence / Profile preview

privosegtor

Development stage: Phase 3
Lead developer: Oculis
Modality: Modified Peptides → Peptides, Small Molecules
Administration: Intravenous

Overview

Privosegtor (OCS-05) is a first-in-class neuroprotective peptoid small molecule (peptidomimetic) being developed for the treatment of neuro-ophthalmic and neurodegenerative disorders. Originally developed by Bionure (a spin-off from IDIBAPS and CSIC) and later licensed from Accure Therapeutics, the drug is designed to activate neurotrophic signaling pathways, thereby protecting retinal ganglion cells and the optic nerve from degeneration. Privosegtor is currently in late-stage clinical development for acute optic neuritis (AON), non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis relapses, with additional potential in glaucoma and geographic atrophy.

Other names: ACT-01ACT01ACT 01BN201BN-201BN 201OCS-05OCS05OCS 05

Targets

MDK (Midkine)SGK2 (Serum/glucocorticoid regulated kinase 2)

Beyond the preview

Go deeper on privosegtor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on privosegtor.